Patents Represented by Attorney, Agent or Law Firm Karl Bozicevic
-
Patent number: 6372214Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPSc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: April 13, 2000Date of Patent: April 16, 2002Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6365359Abstract: Molecules are disclosed that interact with the cellular components involved in conversion of PrPC to PrPSc. The molecules disclosed can be small molecules, peptides or protein analogs, e.g. analogs of PrPC. In one embodiment, these molecules interfere with prion formation and/or replication, e.g. by preventing interactions of proteins involved in a prion complex or by interfering with &bgr;-sheet formation. In another embodiment, the molecules of the invention promote PrPC conversion to PrPSc, e.g. by binding to PrPC and facilitating a conformational change from PrPC to PrPSc.Type: GrantFiled: November 12, 1999Date of Patent: April 2, 2002Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Fred E. Cohen, Thomas L. James, Kiyotoshi Kaneko
-
Patent number: 6364875Abstract: A method and apparatus to alter the shape of the cornea of an eye provides for heating a portion of the cornea to a temperature not exceeding the collagen shrinkage temperature, and applying a pressure differential to a portion of the cornea. The combined effect of elevated temperature and stretching forces leads to permanent residual strains in preferred directions, and thus to a permanent new shape of the cornea. The method is applicable to the correction or reduction of myopia, hyperopia, and astigmatism.Type: GrantFiled: November 2, 1999Date of Patent: April 2, 2002Assignee: Proteus Therapeutics, Inc.Inventor: H. Mark Stanley, III
-
Patent number: 6357670Abstract: The invention is directed to a stable capillary microjet and a monodisperse aerosol formed when the microjet dissociates. A variety of devices and methods are disclosed which allow for the formation of a stream of a first fluid (e.g. a liquid) characterized by forming a stable capillary microjet over a portion of the stream wherein the microjet portion of the stream is formed by a second fluid (e.g. a gas). The second fluid is preferably in a different state from the first fluid—liquid-gas or gas-liquid combinations. However, the first and second fluids may be two different fluids in miscible in each other.Type: GrantFiled: May 11, 2001Date of Patent: March 19, 2002Assignee: Universidad de SevillaInventor: Alfonso Gañán-Calvo
-
Patent number: 6349719Abstract: Aerosolizable formulations are disclosed comprised of a pharmaceutically acceptable carrier, a pharmaceutically active drug or detectably labeled compound and a compound which is recognized by its distinct color, taste and/or smell even when present in a small amount and a low concentration. Examples of such compounds include menthol, peppermint, cinnamon and vanilla flavors and water soluble dyes. The compounds can be designed so that they are only detectable by a specific area of the tongue or seen under a certain wavelength of light. The degree of detection of the color, taste or smell of the compound is an indication of the degree of success in the delivery of an aerosolized formulation to a patient. The formulation is preferably delivered from a device which monitors and records information relating to the patient's respiratory movement and also scans and analyzes the aerosol prior to inhalation.Type: GrantFiled: February 26, 2001Date of Patent: February 26, 2002Assignee: Aradigm CorporationInventor: Igor Gonda
-
Patent number: 6322802Abstract: A method of sterilizing objects as well as the sterilized objects obtained from the method are disclosed. The method involves contacting an object such as a medical device to be reused with polycationic dendrimer under conditions which result in rendering a conformationally altered protein (e.g. a prion) non-infectious. A disinfecting agent or surgical scrub composition which comprises the dendrimers is also disclosed as are gelatin capsules treated with polycationic dendrimers.Type: GrantFiled: January 31, 2000Date of Patent: November 27, 2001Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Surachai Supattapone, Michael R. Scott
-
Patent number: 6306822Abstract: Phosphopeptides which significantly reduce bone loss or weakening are provided by the invention. Also provided is a method for treating or preventing any condition associated with bone loss or weakening by administering the phosphopeptides by oral or injectable means.Type: GrantFiled: November 16, 1998Date of Patent: October 23, 2001Assignee: Big Bear Bio, Inc.Inventors: Yoshinari Kumagai, Akira Otaka
-
Patent number: 6300108Abstract: Electroporation is performed in a controlled manner in either individual or multiple biological cells or biological tissue by monitoring the electrical impedance, defined herein as the ratio of current to voltage in the electroporation cell. The impedance detects the onset of electroporation in the biological cell(s), and this information is used to control the intensity and duration of the voltage to assure that electroporation has occurred without destroying the cell(s). This is applicable to electroporation in general. In addition, a particular method and apparatus are disclosed in which electroporation and/or mass transfer across a cell membrane are accomplished by securing a cell across an opening in a barrier between two chambers such that the cell closes the opening. The barrier is either electrically insulating, impermeable to the solute, or both, depending on whether pore formation, diffusive transport of the solute across the membrane, or both are sought.Type: GrantFiled: July 21, 1999Date of Patent: October 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Boris Rubinsky, Yong Huang
-
Patent number: 6299145Abstract: The present invention provides aeration methods using spherical gas bubbles having a size on the order of 0.1 to 100 microns in size. A device of the invention for producing a monodispersion of bubbles includes a source of a stream of gas which is forced through a liquid held under pressure in a pressure chamber with an exit opening therein. The stream of gas surrounded by the liquid in the pressure chamber flows out of an exit orifice of the chamber into a liquid thereby creating a monodispersion of bubbles with substantially uniform diameter. The bubbles are small in size and produced with a relatively small amount of energy relative to comparable systems. Applications of the aeration technology range from oxygenating sewage with monodispersions of bubbles to oxygenation of water for fish maintenance.Type: GrantFiled: June 27, 2000Date of Patent: October 9, 2001Assignee: Universidad de SevillaInventor: Alfonso Gañan-Cálvo
-
Patent number: 6295986Abstract: A method for producing a nozzle useful in generating a fine aerosol for delivery of a therapeutic or diagnostic agent is provided. The method comprises treating a thin, preferably flexible material having partially formed nozzles with a plasma which alters the size and shape of the nozzles. The pores in the nozzles so formed preferably have an unflexed exit aperture diameter in the range of about 0.5 to about 25 microns, depending on the size of the aerosol particles desired for a given application. The pores in the nozzles can have a variety of shapes and can be distributed in a variety of patterns. An elevated area can be formed around the exit aperture of the nozzle in order to prevent intrusion of liquid back into the nozzle. A method of producing an aerosolization device incorporating such a nozzle is also provided.Type: GrantFiled: January 12, 2000Date of Patent: October 2, 2001Assignee: Aradigm CorporationInventors: Rajesh S. Patel, Sudarsan Srinivasan
-
Patent number: 6291498Abstract: A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.Type: GrantFiled: September 15, 2000Date of Patent: September 18, 2001Inventor: Gerald Horn
-
Patent number: 6290954Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: March 6, 1998Date of Patent: September 18, 2001Assignee: The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6260970Abstract: A method for detecting the presence of eye disease in a human eye. A test subject is presented with a fixation target positioned on a colored planar surface. The test subject focuses a test eye on the fixation target and positions the test eye a sufficient separation distance from the fixation target and aligns the test eye relative to said fixation target so that the test subject's central and peripheral visual health can be tested. Additional marks are presented on the planar surface for detection by said test subject using the peripheral vision of the test eye. The additional marks are primarily the same level of black-white contrast as the planar surface but different in hue to create color contrast symbols, and are presented within the field of vision of an eye not afflicted with the disease for which testing is being conducted. In this way, the presence of eye disease can be detected if the additional marks are not visible to the test subject.Type: GrantFiled: August 30, 1999Date of Patent: July 17, 2001Assignee: Health Performance, Inc.Inventor: Gerald Horn
-
Patent number: 6250298Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation.Type: GrantFiled: September 7, 2000Date of Patent: June 26, 2001Assignee: Aradigm CorporationInventors: Igor Gonda, Reid M. Rubsamen, Stephen J. Farr
-
Patent number: 6248378Abstract: The invention is directed to production of particles for introduction into food using a stable microjet and a monodisperse aerosol formed when the microjet dissociates. A variety of devices and methods are disclosed which allow for the formation of a stream of a first fluid (e.g. a liquid) characterized by forming a stable capillary microjet over a portion of the stream wherein the microjet portion of the stream is formed by a second fluid (e.g. a gas).Type: GrantFiled: December 21, 1999Date of Patent: June 19, 2001Assignee: Universidad de SevillaInventor: Alfonso Gañán-Calvo
-
Patent number: 6241159Abstract: The object of the present invention is a liquid atomization procedure that uses appropriate geometric parameters and physical properties to ensure that the liquid to be atomized is discharged as a continuous, steady capillary microjet through a suitable orifice. The procedure relies on the microwithdrawal effect undergone by a liquid-gas interface when the gas is withdrawn from a point (orifice) near the liquid surface. The invented procedure is applicable to any mechanism involving homogeneous atomization of liquids (particularly electronic fuel injection).Type: GrantFiled: August 16, 2000Date of Patent: June 5, 2001Assignee: Universidad de SevillaInventors: Alfonso Gañán-Calvo, Antonio Barrero Ripoll
-
Patent number: 6234402Abstract: The invention is directed to a stable capillary microjet and a monodisperse aerosol formed when the microjet dissociates. A variety of devices and methods are disclosed which allow for the formation of a stream of a first fluid (e.g. a liquid) characterized by forming a stable capillary microjet over a portion of the stream wherein the microjet portion of the stream is formed by a second fluid (e.g. a gas). The second fluid is preferably in a different state from the first fluid—liquid-gas or gas-liquid combinations. However, the first and second fluids may be two different fluids in miscible in each other.Type: GrantFiled: June 27, 2000Date of Patent: May 22, 2001Assignee: Universidad de SevillaInventor: Alfonso Gañán-Calvo
-
Patent number: 6230706Abstract: A nozzle comprised of a thin, flexible membrane material having a plurality of pores is disclosed. In one embodiment, the pores have an unflexed exit aperture diameter in the range of about 0.5 to about 2 microns (preferably about 1 micron) and are positioned substantially uniformly in the material, preferably about 50 microns apart. The nozzle preferably has a conical or trumpet-shaped cross-section. In another aspect of the invention, the exit aperture of the nozzle is surrounded by an elevated area protruding above the substantially planar exit side of the membrane in order to prevent intrusion of liquid back into the nozzle. The nozzle can be used to form an aerosol containing a pharmaceutical composition from the exit side of the nozzle upon forcible application of the composition to the entrance side of the nozzle. This aerosol can be used to administer the pharmaceutical composition, for example, to the eye or to a selected portion of the respiratory tract.Type: GrantFiled: June 5, 2000Date of Patent: May 15, 2001Assignee: Aradigm CorporationInventors: Igor Gonda, Jeffrey A. Schuster, Rajesh S. Patel
-
Patent number: 6221614Abstract: Devices such as flow through columns, substrates such as spherical polymer beads, and methods of using such to remove prions from any liquid sample are disclosed. A surface of a substrate is coated with a prion complexing agent, such as a salt of phosphotungstic acid. Blood or plasma passing through a column containing beads coated with prion complexing agent are rendered prion free.Type: GrantFiled: January 20, 1999Date of Patent: April 24, 2001Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Patent number: 6214565Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSc is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.Type: GrantFiled: October 9, 1998Date of Patent: April 10, 2001Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar